Broker change

hVIVO PLC

08 January 2024

 

hVIVO plc

("hVIVO" or the "Company")

Appointment of Nominated Adviser and Joint Broker

hVIVO plc (AIM & Euronext: HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces the appointment of Cavendish Capital Markets Limited as Nominated Adviser and Joint Broker and Peel Hunt LLP as Joint Broker with immediate effect.

For further information please contact:

hVIVO plc		[phone]
Yamin 'Mo' Khan, Chief Executive Officer Stephen Pinkerton, Chief Financial Officer
Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)			[phone]
Geoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward
Peel Hunt LLP (Joint Broker)			[phone]
James Steel, Dr Christopher Golden
Davy (Euronext Growth Adviser and Joint Broker)			[phone]
Anthony Farrell, Niall Gilchrist
Walbrook PR (Financial PR & IR) Stephanie Cuthbert / Phillip Marriage / Louis Ashe-Jepson		[phone] or [e-mail] [phone] / [phone] / [phone]

Notes to Editors

About hVIVO

hVIVO plc (ticker: HVO) (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.

The Group's fast-growing services business includes a unique portfolio of 11 human challenge models, with a number of new models under development, to test a broad range of infectious and respiratory disease products. The Company has world class challenge agent manufacturing, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services.

hVIVO runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialised on-site virology and immunology laboratory, and its clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capability via its FluCamp volunteer screening facilities in London and Manchester.

Existing Board - AIM Rule 17 Disclosure

The Company announces the following additional director disclosures pursuant to AIM Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies.

Elaine Sullivan

In addition to the disclosures made in Elaine Sullivan's announcement of appointment on 24 November 2020, the following directorships are disclosed:

Company	Current, or last 5 years
Carrick Therapeutics Limited	Directorship held in last 5 years, at time of appointment to hVIVO

Brendan Buckley

The following directorships were disclosed incorrectly in the Company's Admission Document dated 9 December 2019:

Company	Disclosure
Irish Platform for Patients' Organisations, Science and Industry Company Limited	Directorship held more than 5 years prior to publication of the Admission Document and therefore should not have been disclosed in the Admission Document

Cathal Friel

In addition to the disclosures made in the Admission Document dated 9 December 2019, the following directorships are disclosed:

Company	Current, or last 5 years
Amryt Pharma Holdings Limited	Directorship held in last 5 years at time of Admission Document publication
Venn Life Sciences Limited Venn Life Sciences (Germany) GmbH Venn Life Sciences (Ireland) Limited Venn Life Sciences (NI) Limited Venn Life Sciences (Australia) Pty Ltd Venn Life Sciences Inc. Venn Life Sciences Legal Representation B.V Venn Life Sciences ED B.V. Venn Life Sciences (France) SAS Venn Life Sciences B.V.	Current directorship at the time of Admission Document publication

The following directorships were disclosed incorrectly in the Company's Admission Document dated 9 December 2019:

Company	Current, or last 5 years
Amryt Pharma plc	Incorrectly disclosed as a directorship
Fastnet Hydrocarbons Limited Raglan Natural Resources Limited	Directorship held in last 5 years at time of Admission Document publication. These directorships were disclosed as current directorships in the Admission Document
Fitzwilliam Place Capital Limited	Directorship held more than 5 years prior to Admission Document publication and therefore should not have been disclosed in the Admission Document

 

END